Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35

Benzinga · 1d ago
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.